Telix Pharmaceuticals (TLX) Operating Leases (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Operating Leases for 3 consecutive years, with $62.1 million the latest figure, recorded in Q4 2025.

• Quarterly Operating Leases rose 979.8% year-over-year to $62.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $62.1 million (up 979.8% YoY) and the FY2025 annual result came in at $62.1 million, up 1131.3% from the prior year.
• Operating Leases climbed to $62.1 million in Q4 2025 per TLX's latest filing, from $5.7 million in the prior quarter.
• Over the last five years, Operating Leases for TLX reached as high as $62.1 million in Q4 2025 and fell as low as $5.4 million in Q4 2023.
• A 3-year average of $24.4 million and a median of $5.7 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases advanced 6.04% — and 2025, when it jumped 979.8%.
• Year by year, Operating Leases stood at $5.4 million in 2023, then climbed by 6.04% to $5.7 million in 2024, then soared by 979.8% to $62.1 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $62.1 million, $5.7 million, and $5.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.